Agendia to Unveil Robust Suite of Data at 2024 ASCO
Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
Read More
German Gynecological Oncology Group (AGO) includes BluePrint® in Guidelines
German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines
Read More
Agendia Announces New I-SPY2 Data Showcasing Ability of New Signature ImPrintTN
Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
Read More
Agendia Presents Data from FLEX Study at Miami Breast 2024
Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
Read MoreAgendia Reports First Patient Enrolled in DEBRA Trial Using MammaPrint
MammaPrint 70-gene signature to aid in evaluation of de-escalation of radiation therapy in Stage I, Hormone Sensitive, HER2-Negative breast cancer
Read More
Agendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan’s Dr. Erin Cobain GalleryAgendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan’s Dr. Erin Cobain
Agendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan’s Dr. Erin Cobain
SWOG S2206 will use MammaPrint® breast cancer recurrence test to examine response to immunotherapy in women with high-risk HR+ breast cancer.
Read More
MammaPrint® approved for Reimbursement in the Netherlands
The Dutch National Healthcare Institute (ZIN) has approved MammaPrint® for inclusion in the Dutch National health insurance basic package with immediate effect.
Read More
Agendia® Names Joyce A. O’Shaughnessy, MD as New Principal Investigator for FLEX Study
Renowned breast oncologist and clinical researcher to lead ongoing efforts to accelerate diagnostic discoveries and enable precision oncology through real-world evidence-based study platform
Read MoreNew Neoadjuvant Trial (MINT) Confirms the Predictive Utility of MammaPrint + BluePrint
The newly published prospective Multi-Institutional Neoadjuvant Therapy MammaPrint Project I (MINT) trial is the first neoadjuvant study to show that nodal downstaging in response to neoadjuvant therapy can be predicted by MammaPrint + BluePrint, Agendia’s advanced genomic assays.
Read MoreAgendia Appoints Ronald Andrews and David Schreiber to Board of Directors
Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, today announced the appointment of industry veterans Ronald (Ron) Andrews and David Schreiber to the company’s Board of Directors.
Read More
